Skinject
Private Company
Funding information not available
Overview
Skinject is a private, pre-revenue biotech company advancing a dissolvable microneedle patch for the treatment of non-melanoma skin cancers. Its technology, co-invented at the University of Pittsburgh and Carnegie Mellon University, aims to deliver a chemotherapy agent intradermally to kill cancer cells and stimulate an immune response, potentially reducing recurrence. The company is in the pre-clinical/development stage, targeting a large and growing market dominated by surgical procedures, with a regimen designed for simple, weekly in-office application over three weeks.
Technology Platform
Dissolvable microneedle array (MNA) patch for transdermal delivery of a chemotherapeutic agent. The needles, made from an FDA-approved cellulose-like material, penetrate the skin and dissolve, releasing the drug to kill cancer cells and stimulate an immune response.
Opportunities
Risk Factors
Competitive Landscape
Skinject competes in the non-melanoma skin cancer treatment space, dominated by surgical procedures (Mohs surgery, excision) and destructive techniques (cryotherapy, electrodessication). Other non-invasive competitors include topical therapies (e.g., imiquimod, 5-fluorouracil) and photodynamic therapy. Skinject's proposed differentiator is its targeted, intradermal delivery via a dissolvable patch, aiming for superior efficacy and convenience compared to existing topicals and less invasiveness than surgery.